A Comprehensive Review on Importance and Quantitation of Atypical Antipsychotic Drugs and their Active Metabolites in Commercial Dosage Forms

Author(s): Habibur Rahman, S.K. Manirul Haque*, Masoom Raza Siddiqui

Journal Name: Current Pharmaceutical Analysis

Volume 16 , Issue 8 , 2020


DOI : 10.2174/1573412915666190328214323

  Journal Home
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Schizophrenia is a severe mental illness that affects more than twenty-one million people throughout the world. Schizophrenia also causes early death. Schizophrenia and other related psychotic ailments are controlled by the prescription of antipsychotic drugs, which act by blocking certain chemical receptors in the brain and thus relieves the symptoms of psychotic disorder. These drugs are present in the different dosage forms in the market and provided in a certain amount as per the need of the patients.

Objective: Since such medications treat mental disorders, it is very important to have a perfect and accurate dose so that the risk factor is not affected by a higher or lower dose, which is not sufficient for the treatment. For accurate assay of these kinds of drugs, different analytical methods were developed ranging from older spectrophotometric techniques to latest hyphenated methods.

Results: The current review highlights the role of different analytical techniques that were employed in the determination and identification of antipsychotic drugs and their metabolites. Techniques such as spectrophotometry, fluorimetry, liquid chromatography, liquid chromatography-mass spectrometry, gas chromatography, and gas chromatography-mass spectrometry employed in the method development of such antipsychotic drugs were reported in the review. Different metabolites, identified using the hyphenated techniques, were also mentioned in the review. The synthesis pathways of few of the metabolites were mentioned.

Conclusion: The review summarizes the analyses of different antipsychotic drugs and their metabolites. A brief introduction of illnesses and their symptoms and possible medications were highlighted. Synthesis pathways of the associated metabolites were also mentioned.

Keywords: Schizophrenia, antipsychotic drugs, analytical techniques, dosage forms, metabolites, hyphenated methods.

[1]
Lieberman, J.A.; Michael, B.F. Psychotic Disorders. New Eng-land. J. Med., 2018, 379, 270-280.
[2]
Health 24: Life a great life https://www.health24.com/Mental-Health/Brain/Neurological-conditions/12-types-of
[3]
Overview of psychosis MedLineplus: psychotic disorders National alliance of mental illness: About the first episodes of psychosis, https://www.webmd.com/schizophrenia/guide/mental-health-psychotic-disorders#1
[4]
Sohn, M.; Moga, D.C.; Blumenschein, K.; Talbert, J. National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore), 2016, 95(23)e3784
[http://dx.doi.org/10.1097/MD.0000000000003784] [PMID: 27281081]
[5]
Breier, A.; Schreiber, J.L.; Dyer, J.; Pickar, D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch. Gen. Psychiatry, 1991, 48(3), 239-246.
[http://dx.doi.org/10.1001/archpsyc.1991.01810270051007] [PMID: 1671741]
[6]
Baldessarini, R.J. A summary of current knowledge of tardive dyskinesia. Encephale, 1988, 14(Spec No), 263-268.
[PMID: 2905654]
[7]
Levenson, J.L. Neuroleptic malignant syndrome. Am. J. Psychiatry, 1985, 142(10), 1137-1145.
[http://dx.doi.org/10.1176/ajp.142.10.1137] [PMID: 2863986]
[8]
Sovner, R.; Dimascio, A.; Killam, F. Extrapyrmidal syn-dromes and the other neurological side effects of psycho-tropic drugs. Psychopharmacology: A Generation of Pro-gress; Lipton, M.A.; DiMascio, A. Killam, F., Eds. Raven Press. New York, 1978, pp. 1021-1032.
[9]
Náhunek, K.; Rodová, A.; Svestka, J.; Kamenická, V.; Cesková, E.; Misurec, J. Clinical experience with clozapine in endogenous depression. Act. Nerv. Super. (Praha), 1973, 15(2), 111-111.
[PMID: 4752638]
[10]
Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry, 1988, 45(9), 789-796.
[http://dx.doi.org/10.1001/archpsyc.1988.01800330013001] [PMID: 3046553]
[11]
Shuman, M.; Lee Demler, T.; Trigoboff, E.; Opler, L.A. Hematologic impact of antibiotic administration on patients taking clozapine. Innov. Clin. Neurosci., 2012, 9(11-12), 18-30.
[PMID: 23346515]
[12]
Wu, Y.S.; Huang, T.L. Low-dose clozapine therapy for a bipolar patient with abnormal levels of thyroid function and anti-thyroid antibodies. Psychiatr. Danub., 2015, 27(2), 198-200.
[PMID: 26057319]
[13]
Gentile, S. Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights. CNS Drugs, 2007, 21(5), 367-387.
[http://dx.doi.org/10.2165/00023210-200721050-00002] [PMID: 17447826]
[14]
Nelson, J.C.; Papakostas, G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry, 2009, 166(9), 980-991.
[http://dx.doi.org/10.1176/appi.ajp.2009.09030312] [PMID: 19687129]
[15]
Chen, J.; Gao, K.; Kemp, D.E. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr. Opin. Psychiatry, 2011, 24(1), 10-17.
[http://dx.doi.org/10.1097/YCO.0b013e3283413505] [PMID: 21088586]
[16]
Rummel-Kluge, C.; Komossa, K.; Schwarz, S.; Hunger, H.; Schmid, F.; Kissling, W.; Davis, J.M.; Leucht, S. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr. Bull., 2012, 38(1), 167-177.
[http://dx.doi.org/10.1093/schbul/sbq042] [PMID: 20513652]
[17]
Petty, R.G. Prolactin and antipsychotic medications: mechanism of action. Schizophr. Res., 1999, 35(Suppl.), S67-S73.
[http://dx.doi.org/10.1016/S0920-9964(98)00158-3] [PMID: 10190227]
[18]
Gruen, P.H.; Sachar, E.J.; Langer, G.; Altman, N.; Leifer, M.; Frantz, A.; Halpern, F.S. Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch. Gen. Psychiatry, 1978, 35(1), 108-116.
[http://dx.doi.org/10.1001/archpsyc.1978.01770250110011] [PMID: 23087]
[19]
Sumiyoshi, T. Antipsychotic treatments; focus on lurasidone. Front. Pharmacol., 2013, 4, 102.
[http://dx.doi.org/10.3389/fphar.2013.00102] [PMID: 23986702]
[20]
Ramachandraiah, C.T.; Subramaniam, N.; Tancer, M. The story of antipsychotics: Past and present. Indian J. Psychiatry, 2009, 51(4), 324-326.
[http://dx.doi.org/10.4103/0019-5545.58304] [PMID: 20048463]
[21]
Shen, W.W. A history of antipsychotic drug development. Compr. Psychiatry, 1999, 40(6), 407-414.
[http://dx.doi.org/10.1016/S0010-440X(99)90082-2] [PMID: 10579370]
[22]
My, V.M.C. Virtual medical centre., https://www.myvmc.com/treatments/atypical-antipsychotics
[23]
Nordström, A.L.; Nyberg, S.; Olsson, H.; Farde, L. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Arch. Gen. Psychiatry, 1998, 55(3), 283-284.
[http://dx.doi.org/10.1001/archpsyc.55.3.283] [PMID: 9510228]
[24]
Kendrick, T. The newer, ‘atypical’ antipsychotic drugs--their development and current therapeutic use. Br. J. Gen. Pract., 1999, 49(446), 745-749.
[PMID: 10756621]
[25]
King, D.J. Drug treatment of the negative symptoms of schizophrenia. Eur. Neuropsychopharmacol., 1998, 8(1), 33-42.
[http://dx.doi.org/10.1016/S0924-977X(97)00041-2] [PMID: 9452938]
[26]
Borison, R.L. Recent advances in the pharmacotherapy of schizophrenia. Harv. Rev. Psychiatry, 1997, 4(5), 255-271.
[http://dx.doi.org/10.3109/10673229709030552] [PMID: 9385002]
[27]
World Health Organization Schizophrenia, https://www.who.int/news-room/fact-sheets/detail/schizophrenia
[28]
Young, C.R.; Bowers, M.B., Jr; Mazure, C.M. Management of the adverse effects of clozapine. Schizophr. Bull., 1998, 24(3), 381-390.
[http://dx.doi.org/10.1093/oxfordjournals.schbul.a033333] [PMID: 9718630]
[29]
Muench, J.; Hamer, A.M. Adverse effects of antipsychotic medications. Am. Fam. Physician, 2010, 81(5), 617-622.
[PMID: 20187598]
[30]
Farah, A. Atypicality of atypical antipsychotics. Prim. Care Companion J. Clin. Psychiatry, 2005, 7(6), 268-274.
[http://dx.doi.org/10.4088/PCC.v07n0602] [PMID: 16498489]
[31]
Lee, P.E.; Gill, S.S.; Rochon, P. Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia. Neuropsychiatr. Dis. Treat., 2006, 2(4), 521-529.
[http://dx.doi.org/10.2147/nedt.2006.2.4.521] [PMID: 19412500]
[32]
Uçok, A.; Gaebel, W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry, 2008, 7(1), 58-62.
[http://dx.doi.org/10.1002/j.2051-5545.2008.tb00154.x] [PMID: 18458771]
[33]
Rasimas, J.J.; Liebelt, E.L. Adverse effects and toxicity of the atypical antipsychotics: what is important for the pediatric emergency medicine practitioner. Clin. Pediatr. Emerg. Med., 2012, 13(4), 300-310.
[http://dx.doi.org/10.1016/j.cpem.2012.09.005] [PMID: 23471213]
[34]
Raymond, L. Adverse effects from atypical antipsychotics. Mental Health Clinician, 2013, 3(3), 114-114.
[http://dx.doi.org/10.9740/mhc.n167197]
[35]
Walker, E.; Tessner, K. Schizophrenia. Perspect. Psychol. Sci., 2008, 3(1), 30-37.
[http://dx.doi.org/10.1111/j.1745-6916.2008.00059.x] [PMID: 26158667]
[36]
Gottesman, I.I. Schizophrenia genesis: The origins of mad-ness; W.H. & Freeman Company: New York, 1991.
[37]
Pirjo, M.; Juha, V.; Peter, B.J.; Graham, K.M.; Hannu, K.; Pekka, T.; Jouko, M.; Paivikki, T.; Karl-Erik, W.; Johanna, K.; Erika, L.; Matti, I. Predictors of schizophrenia-a review. Brit-ish. Med. Bull., 2005, 73-74, 1-15.
[http://dx.doi.org/10.1093/bmb/ldh046]
[38]
Smith, M.J.; Greenberg, J.S.; Sciortino, S.A.; Sandoval, G.M.; Lukens, E.P. Life course challenges faced by siblings of individuals with schizophrenia may increase risk for depressive symptoms. Ment. Health Fam. Med., 2016, 12(1), 147-151.
[http://dx.doi.org/10.25149/1756-8358.1201003] [PMID: 27175217]
[39]
Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K.R.; Walters, E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry, 2005, 62(6), 593-602.
[http://dx.doi.org/10.1001/archpsyc.62.6.593] [PMID: 15939837]
[40]
Naqvi, T.Z.; Naqvi, S.S.; Merz, C.N. Gender differences in the link between depression and cardiovascular disease. Psychosom. Med., 2005, 67(Suppl. 1), S15-S18.
[http://dx.doi.org/10.1097/01.psy.0000164013.55453.05] [PMID: 15953793]
[41]
Whiteford, H.A.; Degenhardt, L.; Rehm, J.; Baxter, A.J.; Ferrari, A.J.; Erskine, H.E.; Charlson, F.J.; Norman, R.E.; Flaxman, A.D.; Johns, N.; Burstein, R.; Murray, C.J.L.; Vos, T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet, 2013, 382(9904), 1575-1586.
[http://dx.doi.org/10.1016/S0140-6736(13)61611-6] [PMID: 23993280]
[42]
Datta, T.; Solomon, A.J. Clozapine-induced myocarditis. Oxf. Med. Case Rep., 2018, 2018(1)omx080
[http://dx.doi.org/10.1093/omcr/omx080] [PMID: 29345690]
[43]
Wenthur, C.J.; Lindsley, C.W. Classics in chemical neuroscience: clozapine. ACS Chem. Neurosci., 2013, 4(7), 1018-1025.
[http://dx.doi.org/10.1021/cn400121z] [PMID: 24047509]
[44]
Kumar, P.N.S.; Anish, P.K.; Rajmohan, V. Olanzapine has better efficacy compared to risperidone for treatment of nega-tive symptoms in schizophrenia. Int. J. Psychiatry, 2016, 58(3), 311-316.
[45]
Fuller, R.W.; Snoddy, H.D. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res. Commun. Chem. Pathol. Pharmacol., 1992, 77(1), 87-93.
[PMID: 1359615]
[46]
Bhana, N.; Foster, R.H.; Olney, R.; Plosker, G.L. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs, 2001, 61(1), 111-161.
[http://dx.doi.org/10.2165/00003495-200161010-00011] [PMID: 11217867]
[47]
Komossa, K.; Rummel-Kluge, C.; Schmid, F.; Hunger, H.; Schwarz, S.; El-Sayeh, H.G.G.; Kissling, W.; Leucht, S. Aripiprazole versus other atypical antipsychotics for schizo-phrenia Cochrane Database Sys. Rev., 2009, 4
[48]
Riedel, M.; Müller, N.; Strassnig, M.; Spellmann, I.; Severus, E.; Möller, H.J. Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatr. Dis. Treat., 2007, 3(2), 219-235.
[http://dx.doi.org/10.2147/nedt.2007.3.2.219] [PMID: 19300555]
[49]
Green, B. Zotepine: a clinical review. Expert Opin. Drug Metab. Toxicol., 2009, 5(2), 181-186.
[http://dx.doi.org/10.1517/17425250802670482] [PMID: 19199377]
[50]
Citrome, L. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin. Drug Metab. Toxicol., 2010, 6(12), 1551-1564.
[http://dx.doi.org/10.1517/17425255.2010.531259] [PMID: 21034370]
[51]
Arif, S.A.; Mitchell, M.M. Iloperidone: A new drug for the treatment of schizophrenia. Am. J. Health Syst. Pharm., 2011, 68(4), 301-308.
[http://dx.doi.org/10.2146/ajhp100079] [PMID: 21289324]
[52]
Plosker, G.L.; Deeks, E.D. Asenapine: A review in schizo-phrenia. CNS Drugs, 2016, 30(7), 655-666.
[http://dx.doi.org/10.1007/s40263-016-0363-2] [PMID: 27356921]
[53]
Mirabzadeh, A.; Kimiaghalam, P.; Fadai, F.; Samiei, M.; Daneshmand, R. The therapeutic effectiveness of risperidone on negative symptoms of schizophrenia in comparison with haloperidol: a randomized clinical trial. Basic Clin. Neurosci., 2014, 5(3), 212-217.
[PMID: 25337382]
[54]
Möller, H.J. Risperidone: a review. Expert Opin. Pharmacother., 2005, 6(5), 803-818.
[http://dx.doi.org/10.1517/14656566.6.5.803] [PMID: 15934906]
[55]
Michele, F.; Domenico, D.B.; Giampaolo, P.; Marco, S.; Nico-la, V.; Laura, O.; Elisabetta, F.B.; Felice, I.; Cristiano, A.K.; Andre, F.C.; Andrea, D.B. Lurasidone in the treatment of bipolar depression: systematic review of systematic reviews Hindawi BioMed. Res. Int., 2017.
[56]
Elbe, D.; Carandang, C.G. Focus on ziprasidone: a review of its use in child and adolescent psychiatry. J. Can. Acad. Child Adolesc. Psychiatry, 2008, 17(4), 220-229.
[PMID: 19018327]
[57]
Soares, B.G.; Fenton, M.; Chue, P. Sulpiride for schizophre-nia. Cochrane Database Sys. Rev., 2000, 2CD001162,
[http://dx.doi.org/10.1002/14651858.CD001162] [PMID: 10796605]
[58]
Hale Jean-Michel Azorin Siegfried Kasper Wolfgang Maier Erkka Syvalahti Michael Van Der Burght Mogens Sloth-Nielsen Allan Wehnert, A.; Azorin, J.M.; Kasper, S.; Maier, W.; Syvalahti, E.; Burght, M.V.D.; Mogens, S-N.; Wehnert, A. Sertindole improves both the positive and negative symptoms of schizophrenia: Results of a phase III trial. Int. J. Psychiatry Clin. Pract., 2000, 4(1), 55-62.
[http://dx.doi.org/10.1080/13651500050518406] [PMID: 24927314]
[59]
Murdoch, D.; Keating, G.M. Sertindole: A review of its use in schizophrenia. CNS Drugs, 2006, 20(3), 233-255.
[http://dx.doi.org/10.2165/00023210-200620030-00005] [PMID: 16529528]
[60]
Coleman, M. Human Drug Metabolism: An Introduction, 1st ed; John Wiley & Sons: UK, 2010.
[http://dx.doi.org/10.1002/9780470689332]
[61]
Attia, S.M. Deleterious effects of reactive metabolites. Oxid. Med. Cell. Longev., 2010, 3(4), 238-253.
[http://dx.doi.org/10.4161/oxim.3.4.13246] [PMID: 20972370]
[62]
Kalgutkar, A.S.; Didiuk, M.T. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity? Chem. Biodivers., 2009, 6(11), 2115-2137.
[http://dx.doi.org/10.1002/cbdv.200900055] [PMID: 19937848]
[63]
Kebamo, S.; Tesema, S.; Geleta, B. The role of biotransformation in drug discovery and development. Drug Metab. Tox-icol., 2015, 6, 1-13.
[64]
Mauri, M.C.; Paletta, S.; Maffini, M.; Colasanti, A.; Dragogna, F.; Di Pace, C.; Altamura, A.C. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J., 2014, 13, 1163-1191.
[PMID: 26417330]
[65]
Shen, W.W. The metabolism of atypical antipsychotic drugs: an update. Ann. Clin. Psychiatry, 1999, 11(3), 145-158.
[http://dx.doi.org/10.3109/10401239909147064] [PMID: 10482125]
[66]
Urichuk, L.; Prior, T.I.; Dursun, S.; Baker, G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr. Drug Metab., 2008, 9(5), 410-418.
[http://dx.doi.org/10.2174/138920008784746373] [PMID: 18537577]
[67]
Halpert, J.R.; Guengerich, F.P.; Bend, J.R.; Correia, M.A. Selective inhibitors of cytochromes P450. Toxicol. Appl. Pharmacol., 1994, 125(2), 163-175.
[http://dx.doi.org/10.1006/taap.1994.1061] [PMID: 8171425]
[68]
Zanger, U.M.; Turpeinen, M.; Klein, K.; Schwab, M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem., 2008, 392(6), 1093-1108.
[http://dx.doi.org/10.1007/s00216-008-2291-6] [PMID: 18695978]
[69]
Dragovic, S.; Gunness, P.; Ingelman-Sundberg, M.; Vermeulen, N.P.; Commandeur, J.N. Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab. Dispos., 2013, 41(3), 651-658.
[http://dx.doi.org/10.1124/dmd.112.050484] [PMID: 23297297]
[70]
Kirschbaum, K.M.; Müller, M.J.; Malevani, J.; Mobascher, A.; Burchardt, C.; Piel, M.; Hiemke, C. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J. Biol. Psychiatry, 2008, 9(3), 212-218.
[http://dx.doi.org/10.1080/15622970701361255] [PMID: 17853280]
[71]
Kassahun, K.; Mattiuz, E.; Nyhart, E., Jr; Obermeyer, B.; Gillespie, T.; Murphy, A.; Goodwin, R.M.; Tupper, D.; Callaghan, J.T.; Lemberger, L. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos., 1997, 25(1), 81-93.
[PMID: 9010634]
[72]
Bakken, G.V.; Rudberg, I.; Christensen, H.; Molden, E.; Refsum, H.; Hermann, M. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab. Dispos., 2009, 37(2), 254-258.
[http://dx.doi.org/10.1124/dmd.108.023291] [PMID: 19022943]
[73]
Shiraga, T.; Kaneko, H.; Iwasaki, K.; Tozuka, Z.; Suzuki, A.; Hata, T. Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica, 1999, 29(3), 217-229.
[http://dx.doi.org/10.1080/004982599238623] [PMID: 10219963]
[74]
Mutlib, A.E.; Klein, J.T. Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J. Pharmacol. Exp. Ther., 1998, 286(3), 1285-1293.
[PMID: 9732390]
[75]
Van de W.K.S.F.; Jacobs, P.L; Kemperman, G.J.; Spaans, E.; Peeters, P.A.; Delbressine, L.P.; Van, I.M.L. Metabolism and excretion of asenapine in healthy male subjects. Drug Metab. Dispos., 2011, 39, 580-590.
[76]
Spina, E.; Cavallaro, R. The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opin. Drug Saf., 2007, 6(6), 651-662.
[http://dx.doi.org/10.1517/14740338.6.6.651] [PMID: 17967154]
[77]
Caccia, S.; Pasina, L.; Nobili, A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatr. Dis. Treat., 2012, 8, 155-168.
[http://dx.doi.org/10.2147/NDT.S18059] [PMID: 22570547]
[78]
Prakash, C.; Kamel, A.; Gummerus, J.; Wilner, K. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab. Dispos., 1997, 25(7), 863-872.
[PMID: 9224781]
[79]
Sugnaux, F.R.; Benakis, A. Metabolism of sulpiride: determi-nation of the chemical structure of its metabolites in rat, dog and man. Eur. J. Drug Metab. Pharmacokinet., 1978, 3, 235-248.
[http://dx.doi.org/10.1007/BF03189389]
[80]
Sakamoto, K.; Nakamura, Y.; Aikoh, S.; Baba, T.; Perregaard, J.; Pedersen, H.; Moltzen, E.K.; Mulford, D.J.; Yamaguchi, T. Metabolism of sertindole: identification of the metabolites in the rat and dog, and species comparison of liver microsomal metabolism. Xenobiotica, 1995, 25(12), 1327-1343.
[http://dx.doi.org/10.3109/00498259509061921] [PMID: 8719908]
[81]
Sheehan, J.J.; Sliwa, J.K.; Amatniek, J.C.; Grinspan, A.; Canuso, C.M. Atypical antipsychotic metabolism and excretion. Curr. Drug Metab., 2010, 11(6), 516-525.
[http://dx.doi.org/10.2174/138920010791636202] [PMID: 20540690]
[82]
Zanger, U.M.; Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther., 2013, 138(1), 103-141.
[http://dx.doi.org/10.1016/j.pharmthera.2012.12.007] [PMID: 23333322]
[83]
Prior, T.I.; Chue, P.S.; Tibbo, P.; Baker, G.B. Drug metabolism and atypical antipsychotics. Eur. Neuropsychopharmacol., 1999, 9(4), 301-309.
[http://dx.doi.org/10.1016/S0924-977X(98)00040-6] [PMID: 10422890]
[84]
Mitchell, P.B. Therapeutic drug monitoring of psychotropic medications. Br. J. Clin. Pharmacol., 2000, 49(4), 303-312.
[http://dx.doi.org/10.1046/j.1365-2125.2000.00174.x] [PMID: 10759685]
[85]
Molden, E.; Lunde, H.; Lunder, N.; Refsum, H. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther. Drug Monit., 2006, 28(6), 744-749.
[http://dx.doi.org/10.1097/01.ftd.0000249944.42859.bf] [PMID: 17164689]
[86]
Iwahashi, K. Olanzapine metabolism by CYP1A2/CYP2D6 and hyperglycaemia. Acta Neuropsychiatr., 2004, 16(4), 229-230.
[http://dx.doi.org/10.1111/j.0924-2708.2004.00089.x] [PMID: 26984311]
[87]
Shobo, M.; Kondo, Y.; Yamada, H.; Mihara, T.; Yamamoto, N.; Katsuoka, M.; Harada, K.; Ni, K.; Matsuoka, N. Norzotepine, a major metabolite of zotepine, exerts atypical anti-psychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J. Pharmacol. Experimen. Therap., 2010, 333, 772-781.
[PMID: 20223878]
[88]
Citrome, L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int. J. Clin. Pract., 2009, 63(8), 1237-1248.
[http://dx.doi.org/10.1111/j.1742-1241.2009.02142.x] [PMID: 19624791]
[89]
Gandhimathi, R.; Vijayaraj, S.; Jyothirmaie, M.P. Method development and validation of uvspectroscopic method for estimation of asenapine maleate in bulk and tablet formulation. Int. J. Med. Chem. Anal., 2012, 2, 85-90.
[90]
Fang, J.; Bourin, M.; Baker, G.B. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch. Pharmacol., 1999, 359(2), 147-151.
[http://dx.doi.org/10.1007/PL00005334] [PMID: 10048600]
[91]
Mannens, G.; Huang, M.L.; Meuldermans, W.; Hendrickx, J.; Woestenborghs, R.; Heykants, J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab. Dispos., 1993, 21(6), 1134-1141.
[PMID: 7507814]
[92]
Cruz, M.P. Lurasidone HCl (Latuda), an oral, once-daily atypical antipsychotic agent for the treatment of patients with schizophrenia. P&T, 2011, 36(8), 489-492.
[PMID: 21935296]
[93]
Beedham, C.; Miceli, J.J.; Obach, R.S. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J. Clin. Psychopharmacol., 2003, 23(3), 229-232.
[http://dx.doi.org/10.1097/01.jcp.0000084028.22282.f2] [PMID: 12826984]
[94]
Gauch, R.; Michaelis, W. The metabolism of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e) (1,4)diazepine (clozapine) in mice, dogs and human subjects. Farmaco, Prat., 1971, 26(11), 667-681.
[PMID: 5157780]
[95]
Schaber, G.; Stevens, I.; Gaertner, H.J.; Dietz, K.; Breyer-Pfaff, U. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br. J. Clin. Pharmacol., 1998, 46(5), 453-459.
[http://dx.doi.org/10.1046/j.1365-2125.1998.00822.x] [PMID: 9833598]
[96]
Ring, B.J.; Catlow, J.; Lindsay, T.J.; Gillespie, T.; Roskos, L.K.; Cerimele, B.J.; Swanson, S.P.; Hamman, M.A.; Wrighton, S.A. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J. Pharmacol. Exp. Ther., 1996, 276(2), 658-666.
[PMID: 8632334]
[97]
Linnet, K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum. Psychopharmacol., 2002, 17(5), 233-238.
[http://dx.doi.org/10.1002/hup.403] [PMID: 12404680]
[98]
Wood, M.D.; Scott, C.; Clarke, K.; Westaway, J.; Davies, C.H.; Reavill, C.; Hill, M.; Rourke, C.; Newson, M.; Jones, D.N.; Forbes, I.T.; Gribble, A. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur. J. Pharmacol., 2006, 546(1-3), 88-94.
[http://dx.doi.org/10.1016/j.ejphar.2006.07.008] [PMID: 16925992]
[99]
Martignoni, M.; Groothuis, G.M.; de Kanter, R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol., 2006, 2(6), 875-894.
[http://dx.doi.org/10.1517/17425255.2.6.875] [PMID: 17125407]
[100]
Alamo, C.; Lopez-Munoz, F. The pharmacological role and clinical applications of antipsychotics’active metabolites: pal-iperidone versus risperidone. Clin. Exp. Pharmacol., 2013, 3, 1-12.
[http://dx.doi.org/10.4172/2161-1459.1000117]
[101]
Corena-McLeod, M. Comparative pharmacology of risperidone and paliperidone. Drugs R D., 2015, 15(2), 163-174.
[http://dx.doi.org/10.1007/s40268-015-0092-x] [PMID: 25943458]
[102]
Grimm, S.W.; Richtand, N.M.; Winter, H.R.; Stams, K.R.; Reele, S.B. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br. J. Clin. Pharmacol., 2006, 61(1), 58-69.
[http://dx.doi.org/10.1111/j.1365-2125.2005.02507.x] [PMID: 16390352]
[103]
Grimm, S.W.; Stams, K.R.; Bui, K. In vitro prediction of po-tential metabolic drug interactions for seroquel. Schizophr. Res., 1997, 24, 198-198.
[http://dx.doi.org/10.1016/S0920-9964(97)82567-4]
[104]
von dem Wildenberg, H.M.; Delbressine, L.P.; Kaspersen, F.M.; Wagenaars, G.N.; Jacobs, P.L. Biotransformation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1-H-dibenz[2,3:6,7]oxepin o [4,5-c]pyrrolidine maleate in rats. Arzneimittelforschung, 1990, 40(5), 540-544.
[PMID: 1974431]
[105]
Noda, K.; Suzuki, A.; Okui, M.; Noguchi, H.; Nishiura, M.; Nishiura, N. Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylaminoethoxy)-dibenzo[b,f]thiepine (zotepine) in rat, mouse, dog and man. Arzneimittelforschung, 1979, 29(10), 1595-1600.
[PMID: 42414]
[106]
Ono, S.; Hatanaka, T.; Miyazawa, S.; Tsutsui, M.; Aoyama, T.; Gonzalez, F.J.; Satoh, T. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica, 1996, 26(11), 1155-1166.
[http://dx.doi.org/10.3109/00498259609050260] [PMID: 8948091]
[107]
Andersson, T.; Miners, J.O.; Veronese, M.E.; Tassaneeyakul, W.; Tassaneeyakul, W.; Meyer, U.A.; Birkett, D.J. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol., 1993, 36(6), 521-530.
[http://dx.doi.org/10.1111/j.1365-2125.1993.tb00410.x] [PMID: 12959268]
[108]
Chang, T.K.H.; Gonzalez, F.J.; Waxman, D.J. Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys., 1994, 311(2), 437-442.
[http://dx.doi.org/10.1006/abbi.1994.1259] [PMID: 8203907]
[109]
Inaba, T.; Jurima, M.; Mahon, W.A.; Kalow, W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab. Dispos., 1985, 13(4), 443-448.
[PMID: 2863108]
[110]
Miners, J.O.; Rees, D.L.P. Valente. L.; Veronese, M.E.; Bir-kett, D.E. Human hepatic cytochrome P450 catalyzes the rat-limiting pathway of torsemide metabolism. J. Pharmacol. Exp. Ther., 1995, 272, 1076-1081.
[PMID: 7891318]
[111]
Miners, J.O.; Smith, K.J.; Robson, R.A.; McManus, M.E.; Veronese, M.E.; Birkett, D.J. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol., 1988, 37(6), 1137-1144.
[http://dx.doi.org/10.1016/0006-2952(88)90522-9] [PMID: 3355588]
[112]
Murray, M.; Reidy, G.F. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev., 1990, 42(2), 85-101.
[PMID: 2198606]
[113]
Tassaneeyakul, W.; Birkett, D.J.; Veronese, M.E.; McManus, M.E.; Tukey, R.H.; Quattrochi, L.C.; Gelboin, H.V.; Miners, J.O. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther., 1993, 265(1), 401-407.
[PMID: 8474022]
[114]
Tassaneeyakul, W.; Veronese, M.E.; Birkett, D.J.; Gonzalez, F.J.; Miners, J.O. Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem. Pharmacol., 1993, 46(11), 1975-1981.
[http://dx.doi.org/10.1016/0006-2952(93)90639-E] [PMID: 8267647]
[115]
Thummel, K.E.; Kharasch, E.D.; Podoll, T.; Kunze, K. Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab. Dispos., 1993, 21(2), 350-357.
[PMID: 8097708]
[116]
Veronese, M.E.; Mackenzie, P.I.; Doecke, C.J.; McManus, M.E.; Miners, J.O.; Birkett, D.J. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun., 1991, 175(3), 1112-1118.
[http://dx.doi.org/10.1016/0006-291X(91)91680-B] [PMID: 2025243]
[117]
Wrighton, S.A.; Vandenbranden, M.; Stevens, J.C.; Shipley, L.A.; Ring, B.J.; Rettie, A.E.; Cashman, J.R. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev., 1993, 25(4), 453-484.
[http://dx.doi.org/10.3109/03602539308993982] [PMID: 8313838]
[118]
Katteboina, M.Y.; Pilli, N.R.; Mullangi, R.; Seelam, R.R.; Satla, S.R. LC-MS/MS assay for the determination of lurasidone and its active metabolite, ID-14283 in human plasma and its application to a clinical pharmacokinetic study. Biomed. Chromatogr., 2016, 30(7), 1065-1074.
[http://dx.doi.org/10.1002/bmc.3651] [PMID: 26577488]
[119]
Acttr: The expert of molecule analysis, test, instrumentation, http://www.acttr.com/en/en-faq/en-faq-uv-vis/134-en-faq-uv-vis-advantage-disadvantage.html
[120]
Hasan, N.Y.; Elkawy, M.A.; Elzeany, B.E.; Wagieh, N.E. Stability indicating methods for the determination of clozapine. J. Pharm. Biomed. Anal., 2002, 30(1), 35-47.
[http://dx.doi.org/10.1016/S0731-7085(02)00125-5] [PMID: 12151063]
[121]
El-Didamony, A.M.; Hafeez, S.M.; Ali, I.I. Extractive spec-trophotometric method for the determination of some anti-psychtic drugs using Erichrome Black T. J. Appl. Pharm. Sci., 2015, 5, 26-33.
[http://dx.doi.org/10.7324/JAPS.2015.50605]
[122]
Mohamed, A.A.; Al-Ghannam, S.M. Spectrophotometric determination of clozapine based on its oxidation with bromate in a micellar medium. Farmaco, 2004, 59(11), 907-911.
[http://dx.doi.org/10.1016/j.farmac.2004.07.008] [PMID: 15544796]
[123]
El-Didamony, A.M.; Hafeez, S.M.; Hafez, M.M.A. Spectro-photometric determination of aripiprazole, clozapine ans sul-piride by ion pair extraction in tablets and biological fluids. Int. J. Pharm. Pharm. Sci., 2015, 7, 178-184.
[124]
El-Didamony, A.M.; Hafeez, S.M.; Ali, I.I. Spectrophotomet-ric determination of four selected antipsychotic drugs in dos-age forms and biological fluids. Int. J. Pharm. Sci. Rev. Res., 2014, 28, 52-60.
[125]
Basavaiah, K.; Tharpa, K.; Nagaraju, R.; Hiriyanna, S.G.; Vinaya, K.B. Spectrophotometric determination of antipsy-chotic drug olanzapine in pharmaceuticals. Jordan J. Chem., 2009, 4, 65-76.
[126]
Basavaiah, K.; Abdulrahman, S.A.M.; Vinay, K.B. Simple and Sensitive Spectrophotometric Determination of olanzapine in pharmaceutical formulations using two sulphonphthalein acid dyes. Yao Wu Shi Pin Fen Xi, 2009, 17, 434-442.
[127]
Upadhyay, K.; Asthana, A.; Tiwari, N. Sensitive and selective methods for determination of antipsychotic drug olanzapine in pharmaceuticals. Res. Chem. Intermed., 2013, 39, 2629-2640.
[http://dx.doi.org/10.1007/s11164-012-0786-4]
[128]
Adegoke, O.A.; Thomas, O.E.; Makanjuola, D.M.; Adewole, O.O. Spectrophotometric determination of olanzapine after condensation with p-dimethylaminobenzaldehyde. J. Taibah Univ. Sci., 2014, 8, 248-257.
[http://dx.doi.org/10.1016/j.jtusci.2014.03.007]
[129]
Ali, A.A.A.; Elbashir, A.A. Optimized and validated spectro-photometric method for the determination of olanzapine in pharmaceutical formulations using 1,2,-Naphthoquinone-4-Sulphonate (NQS). Am. Acad. Schol. Res. J., 2012, 4, 51-66.
[130]
Basavaiah, K.; Zenita, O.; Tharpa, K.; Rajendraprasad, N.; Anilkumar, U.R.S.; Hiriyana, G.; Vinay, K.B. Iodimetric assay of olanzapine in pharmaceuticals using iodate and nile blue as reagents. Chem. Ind. Chem. Eng. Q., 2009, 15, 95-102.
[http://dx.doi.org/10.2298/CICEQ0902095B]
[131]
Revanasiddappa, H.D.; Veena, M.A. Highly sensitive spectro-photometric methods for the determination of olanzapine. Eclét. Quím., 2008, 33, 47-52.
[http://dx.doi.org/10.1590/S0100-46702008000300007]
[132]
Rajendraprasad, N.; Basavaiah, K.; Tharpa, K.; Vinay, K.B. Quantitative determination of olanzapine in tablets with visi-ble spectrophotometry using cerium(iv) sulphate and based on redox and complexation reactions. Eur. J. Anal. Chem., 2009, 4, 191-203.
[133]
Rajendraprasad, N.; Basavaiah, K. Determination of olanzap-ine by spectrophotometry using permanganate. Braz. J. Pharm. Sci., 2009, 45, 539-550.
[http://dx.doi.org/10.1590/S1984-82502009000300020]
[134]
Basavaiah, K.; Abdulrahman, S.A.M. Utility of n-bromosuccinimide as an environmental-friendly reagent for sensitive determination of olanzapine in pharmaceuticals. Jordan J. Pharm. Sci., 2011, 4, 209-221.
[135]
Mohamed, A.A. Kinetic and maximum-absorbance spectro-photometric methods for the determination of olanzapine. Monatsh. Chem., 2008, 139(9), 1005-1010.
[http://dx.doi.org/10.1007/s00706-008-0894-4]
[136]
Krebs, A.; Starczewska, B.; Puzanowska-Tarasiewicz, H.; Sledz, J. Spectrophotometric determination of olanzapine by its oxidation with N-bromosuccinimide and cerium(IV)sulfate. Anal. Sci., 2006, 22(6), 829-833.
[http://dx.doi.org/10.2116/analsci.22.829] [PMID: 16772680]
[137]
Basavaiah, K.; Abdulrahman, S.A.M. Sensitive and selective methods for the determination of olanzapine in pharmaceuti-cals using n-bromosuccinimide and two dyes. Int. J. Chemtech Res., 2010, 2, 660-668.
[138]
Vivek, M.P.; Jigar, A.P.; Shweta, S.H.; Sunil, R. First and Sec-ond derivative spectrophotometric methods for determination of olanzapine in pharmaceutical formulation. Int. J. Chemtech Res., 2010, 2, 756-761.
[139]
Firdous, S.; Aman, T.; Nisa, A.U. Determination of olanzap-ine by UV spectrophotometry and non-aqueous titration. J. Chem. Soc. Pak., 2005, 27, 163-167.
[140]
Kumar, S.R.; Gayathri, P.; Duganath, N.; Kiran, C.H.; Sridhar, C.; Jayaveera, K.N. Simultaneous estimation of fluoxetine hcl and olanzapine in bulk drug and pharmaceutical formulation by using uv-visible spectroscopy method. Int. J. Pharm. Sci. Drug Res., 2011, 3, 52-55.
[141]
Jasinska, A.; Nalewajko, E. Batch and flow-injection methods for the spectrophotometric determination of olanzapine. Anal. Chim. Acta, 2004, 508(2), 165-170.
[http://dx.doi.org/10.1016/j.aca.2003.11.069]
[142]
Sahar, R.F.; Najwa, I.A.; Intidhar, D.S. The spectrophotomet-ric determination of olanzapine via coupling with diazotized p-nitroaniline. Iraqi J. Pharm Sci., 2016, 25, 42-49.
[143]
Olajire, A.A.; Olusegun, E.T.; Stephen, N.E. Colorimetric determination of olanzapine via charge-transfer complexation with chloranilic acid. J. Taibah Univ. Sci., 2016, 10, 651-663.
[http://dx.doi.org/10.1016/j.jtusci.2015.12.002]
[144]
Dey, S.; Chauhan, N.; Malairajan, P.; Murugan, R.; Das, R.C.; Ahmad, S. A simple and rapid spectrophotometric determina-tion of aripiprazole in pharmaceutical dosage form. Int. J. Drug Dev. Res., 2011, 3, 205-208.
[145]
Kalaichelvi, R.; Thangabalan, B.; Rao, D.S.; Jayachandran, E. UV spectrophotometric determination of aripiprazole in bulk and pharmaceutical formulation. E-J. Chem., 2009, 6(S1), S87-S90.
[http://dx.doi.org/10.1155/2009/542919]
[146]
Nagamallika, J.; Aruna, M. Development and validation of spectrophotometric method for the estimation of aripiprazole in tablet dosage form. Asian J. Pharm. Anal., 2011, 3, 46-49.
[147]
Sandeep, K.; Induri, M.; Sudhakar, M. Validated spectrophotometric quantification of aripiprazole in pharmaceutical formulations by using multivariate technique. Adv. Pharm. Bull., 2013, 3(2), 469-472.
[PMID: 24312881]
[148]
Jain, R.; Kashaw, S.K.; Jain, R.; Mishra, P.; Kohli, D.V. Visible spectrophotometric method for the determination of aripiprazole in tablets. Indian J. Pharm. Sci., 2011, 73(1), 74-76.
[http://dx.doi.org/10.4103/0250-474X.89760] [PMID: 22131625]
[149]
Subbayamma, A.V.; Rambabu, C. Spectrophotometric deter-mination of aripiprazole in pharmaceutical formulation with MBTH and ferric chloride. Orient. J. Chem., 2008, 24, 677-680.
[150]
Helmy, A.G.; Abdel-Gawad, F.M.; Mohamed, E.F. Spectropho-tometric study on determination of aripiprazole in tablets by charge transfer and ion pair complexation reaction with some acceptors. Asian J. Pharm. Anal., 2012, 2, 12-19.
[151]
Ramya, N.S.; Vijayalakshmi, R.; Dhanaraju, M.D. Spectro-photometric determination of aripiprazole and tapentadol us-ing chloranillic acid reagent. Int. J. Pharm. Sci. Res., 2015, 6, 2052-2055.
[152]
Bagade, S.B.; Narkhede, S.P.; Nikam, D.S.; Sachde, C.K. Devel-opment and validation of UV-spectrophotometric method for determination of quetiapine fumarate in two different dose tablets. Int. J. Chemtech Res., 2009, 1, 898-904.
[153]
Valarmathi, R.; Dhharshini, C.S.D.; Senthamarai, R.; Banu, S.F. Analytical method development of quetiapine fumerate in bulk and its tablet formulation by simple UV spectropho-tometry. Int. J. Drug Dev. Res., 2013, 5, 366-372.
[154]
Vinay, K.B.; Revanasiddappa, H.D. Spectrophotometric de-termination of quetiapine fumarate through ion-pair complex-ation reaction with tropaeolin ooo. Indian J. Chem. Technol., 2012, 19, 205-212.
[155]
Biocompare, The buyer’s guide for life scientists: Bench Tips, https://www.biocompare.com/Bench-Tips/173963-Choosing-the-Best-Detection-Method-Absorbance-vs-Fluorescence
[156]
Darwish, I.; Abdel-Wadood, H.; Abdel-Latif, N. Validated spectrophotometric and fluorimetric methods for analysis of clozapine in tablets and urine. Ann. Chim., 2005, 95(5), 345-356.
[http://dx.doi.org/10.1002/adic.200590039] [PMID: 16477942]
[157]
Mostafa, I.M.; Omar, M.A.; Nagy, D.M.; Derayea, S.M. Anal-ysis of quetiapine in human plasma using fluorescence spec-troscopy. Spectropchim. Acta Part A: Molecul. Biomol. Spec-tros., 2018, 196, 196-201.
[158]
El-Enany, N.; Belal, F.; El-Brashy, A.; El-Bahy, N. Spectro-fluorimetric determination of flupentixol dihydrochloride and quetiapine in pharmaceutical preparations and spiked human plasma via oxidation with cerium (IV). Anal. Chem. Indian J., 2009, 8, 325-333.
[159]
McMaster, M.C. HPLC A Practical User’s Guide, 2nd ed; Wiley & Sons: New York, 2007.
[http://dx.doi.org/10.1002/0470079096]
[160]
Rosland, M.; Szeto, P.; Procyshyn, R.; Barr, A.M.; Wasan, K.M. Determination of clozapine and its metabolite, norclozapine in various biological matrices using high-performance liquid chromatography. Drug Dev. Ind. Pharm., 2007, 33(10), 1158-1166.
[http://dx.doi.org/10.1080/03639040701484338] [PMID: 17963117]
[161]
Liu, Y.Y.; van Troostwijk, L.J.; Guchelaar, H.J. Simultaneous determination of clozapine, norclozapine and clozapine-N-oxide in human plasma by high-performance liquid chromatography with ultraviolet detection. Biomed. Chromatogr., 2001, 15(4), 280-286.
[http://dx.doi.org/10.1002/bmc.73] [PMID: 11438972]
[162]
Mosier, K.E.; Song, J.; McKay, G.; Hubbard, J.W.; Fang, J. Determination of clozapine, and its metabolites, N-desmethylclozapine and clozapine N-oxide in dog plasma using high-performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 783(2), 377-382.
[http://dx.doi.org/10.1016/S1570-0232(02)00655-4] [PMID: 12482480]
[163]
Frahnert, C.; Rao, M.L.; Grasmäder, K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 794(1), 35-47.
[http://dx.doi.org/10.1016/S1570-0232(03)00393-3] [PMID: 12888196]
[164]
Mercolini, L.; Bugamelli, F.; Kenndler, E.; Boncompagni, G.; Franchini, L.; Raggi, M.A. Simultaneous determination of the antipsychotic drugs levomepromazine and clozapine and their main metabolites in human plasma by a HPLC-UV method with solid-phase extraction. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 846(1-2), 273-280.
[http://dx.doi.org/10.1016/j.jchromb.2006.09.019] [PMID: 17045854]
[165]
Shen, Y.L.; Wu, H.L.; Ko, W.K.; Wu, S.M. Simulnaeous de-termination of clozapine, clozapine N-oxide, N-desmethylclozapine, resperidone and 9-hydroxyrisperidone in plasma by high performance liquid chromatography with ultraviolet detection. Anal. Chim. Acta, 2002, 460(2), 201-208.
[http://dx.doi.org/10.1016/S0003-2670(02)00239-8]
[166]
Kaewvichit, S.; Sangsrijan, S.; Sangsrijan, S. Determination of clozapine in human plasma by high performance liquid chro-matography with UV-VIS detector. CMU. J. Nat. Sci., 2010, 9, 29-37.
[167]
Dural, E.; Mergen, G.; Soylemezoglu, T. Optimization and validation of an HPLC-UV method for analysis of clozapine and its major metabolites in human plasma. Turk. J. Pharm. Sci., 2015, 12, 177-186.
[http://dx.doi.org/10.5505/tjps.2015.68077]
[168]
Kaur, H.; Bassi, P.; Monif, T.; Khuroo, A.; Kaur, G. Development and validation of high performance liquid chromatographic method for analysis of clozapine. Pak. J. Pharm. Sci., 2013, 26(3), 465-472.
[PMID: 23625418]
[169]
Tyagi, M.G. Estimation of clozapine in human plasma by high performance liquid chromatography and detection by UV-VIS detector. Asian J. Biochem. Pharm. Res., 2012, 2, 49-53.
[170]
Patil, U.A.; Ghosh, B. Reverse phase liquid chromatographic method for the estimation of clozapine from tablet dosage forms. Int. J. Pharm. Tech. Res., 2009, 1, 733-736.
[171]
Raggi, M.A.; Bugamelli, F.; Mandrioli, R.; De Ronchi, D.; Volterra, V. Development and validation of an HPLC method for the simultaneous determination of clozapine and desmethylclozapine in plasma of schizophrenic patients. Chromatographia, 1999, 49(1-2), 75-80.
[http://dx.doi.org/10.1007/BF02467191]
[172]
Basavaiah, K.; Rajendraprasad, N.; Vinay, K.B. Isocratic high-performance liquid chromatographic assay of olanzapine. Method development and validation ISRN. Anal. Chem., 2014, 1-6.
[173]
D’Arrigo, C.; Migliardi, G.; Santoro, V.; Spina, E. Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. Ther. Drug Monit., 2006, 28(3), 388-393.
[http://dx.doi.org/10.1097/01.ftd.0000211800.66569.c9] [PMID: 16778724]
[174]
Saracino, M.A.; Gandolfi, O.; Dall’olio, R.; Albers, L.; Kenndler, E.; Raggi, M.A. Determination of Olanzapine in rat brain using liquid chromatography with coulometric detection and a rapid solid-phase extraction procedure. J. Chromatogr. A, 2006, 1122(1-2), 21-27.
[http://dx.doi.org/10.1016/j.chroma.2006.04.011] [PMID: 16678187]
[175]
Saracino, M.A.; Koukopoulos, A.; Sani, G.; Amore, M.; Raggi, M.A. Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients. Ther. Drug Monit., 2007, 29(6), 773-780.
[http://dx.doi.org/10.1097/FTD.0b013e31815bde43] [PMID: 18043475]
[176]
Raggi, M.A.; Casamenti, G.; Mandrioli, R.; Volterra, V. A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure. J. Chromatogr. B Biomed. Sci. Appl., 2001, 750(1), 137-146.
[http://dx.doi.org/10.1016/S0378-4347(00)00438-2] [PMID: 11204214]
[177]
Kasper, S.C.; Mattiuz, E.L.; Swanson, S.P.; Chiu, J.A.; Johnson, J.T.; Garner, C.O. Determination of olanzapine in human breast milk by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B Biomed. Sci. Appl., 1999, 726(1-2), 203-209.
[http://dx.doi.org/10.1016/S0378-4347(99)00017-1] [PMID: 10348187]
[178]
Reddy, B.V.; Reddy, K.V.N.S.; Sreeramulu, J.; Kanumula, G.V. Simultaneous determination of olanzapine and fluoxe-tine by HPLC. Chromatographia, 2007, 66(1-2), 111-114.
[http://dx.doi.org/10.1365/s10337-007-0257-z]
[179]
Shah, C.R.; Shah, N.J.; Suhagia, B.N.; Patel, N.M. Simultaneous assay of olanzapine and fluoxetine in tablets by column high-performance liquid chromatography and high-performance thin-layer chromatography. J. AOAC Int., 2007, 90(6), 1573-1578.
[http://dx.doi.org/10.1093/jaoac/90.6.1573] [PMID: 18193734]
[180]
Pathak, A.; Rajput, S.J. Development of a stability-indicating HPLC method for simultaneous determination of olanzapine and fluoxetine in combined dosage forms. J. Chromatogr. Sci., 2009, 47(7), 605-611.
[http://dx.doi.org/10.1093/chromsci/47.7.605] [PMID: 19772736]
[181]
Tantawy, M.A.; Hassan, N.Y.; Elragehy, N.A.; Abdelkawy, M. Simultaneous determination of olanzapine and fluoxetine hydrochloride in capsules by spectrophotometry, TLC-spectrodensitometry and HPLC. J. Adv. Res., 2013, 4(2), 173-180.
[http://dx.doi.org/10.1016/j.jare.2012.05.004] [PMID: 25685415]
[182]
Nandini, R.; Dubhashi, S.D. Development of stability indicating validated HPLC method for quantitative determination of ari-piprazole and its impurities. Der Pharm. Lett., 2010, 2, 1-10.
[183]
Soponar, F.; Sandru, M.; David, V. Quantitative evaluation of aripiprazole and its five related chemical impurities from pharmaceuticals using HPLC-DAD method. Rev. Roum. Chim., 2014, 59, 1037-1046.
[184]
Filijovic, N.D.; Pavlovic, A.; Nikolic, K.; Agbaba, D. Valida-tion of an HPLC method for determination of aripiprazole and its impurities in pharmmaceuticals. Acta Chromatogr., 2014, 26, 13-28.
[http://dx.doi.org/10.1556/AChrom.26.2014.1.15]
[185]
Shimokawa, Y.; Akiyama, H.; Kashiyama, E.; Koga, T.; Miyamoto, G. High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2005, 821(1), 8-14.
[http://dx.doi.org/10.1016/j.jchromb.2005.03.024] [PMID: 15897016]
[186]
Vijaya, K.M.; Muley, P.R. Determination of aripiprazole in bulk drug and solid dosage forms by RP-HPLC meth-od. Indian Pharm., 2005, 4, 71-75.
[187]
Koduri, S.V.; Buchireddy, S.R.; Madhusudhan, G.; Mukkanti, K.; Srinivasulu, P. Stress degradation studies on aripiprazole and development of a validated stability indicating LC method. Chromatographia, 2008, 68(7-8), 635-640.
[http://dx.doi.org/10.1365/s10337-008-0739-7]
[188]
Lancelin, F.; Djebrani, K.; Tabaouti, K.; Kraoul, L.; Brovedani, S.; Paubel, P.; Piketty, M.L. Development and validation of a high-performance liquid chromatography method using diode array detection for the simultaneous quantification of aripiprazole and dehydro-aripiprazole in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 867(1), 15-19.
[http://dx.doi.org/10.1016/j.jchromb.2008.02.026] [PMID: 18356121]
[189]
Akamine, Y.; Yasui-Furukori, N.; Kojima, M.; Inoue, Y.; Uno, T. A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies. J. Sep. Sci., 2010, 33(21), 3292-3298.
[http://dx.doi.org/10.1002/jssc.201000457] [PMID: 21049519]
[190]
Bhanotu, B.; Srinath, P.; Kedarnath, J. Development, estima-tion and validation of aripiprazole in bulk and its pharmaceu-tical formulation by HPLC method. Int. J. Chemtech Res., 2012, 4, 124-128.
[191]
Sastry, B.S.; Gananadhamu, S.; Rao, G.D. RP-HPLC determi-nation of aripiprazole in pharmaceutical formulations. Asian J. Chem., 2009, 21, 6643-6646.
[192]
Mondal, P.; Rani, S.S.; Alekhya, K. A new stability indicating validated method for the determination of aripiprazole in bulk and tablet dosage form using RP- HPLC. Int. J. Pharm. Pharma. Sci., 2013, 5(Suppl. 4), 660-665.
[193]
Kalaichelvi, R.; Thangabalan, B.; Srinivasa, R.D. Validated RP-HPLC method for analysis of aripiprazole in a formulation. J. Chin. Med. Assn., 2010, 7, 827-832.
[http://dx.doi.org/10.1155/2010/935279]
[194]
Dedania, Z.; Dedania, R.; Sheth, N.; Gajra, B.; Patel, J. Devel-opment and validation of a stability-indicating high perfor-mance liquid chromatography assay for aripiprazole in bulk drug substance. Asian J. Pharm. Biol. Res., 2011, 1, 123-128.
[195]
Pai, N.R.; Pusalkar, D.A. Development and validation of liq-uid chromatographic method for aripiprazole. Pharm. Sin., 2012, 3(5), 526-535.
[196]
Ravindra, N.; Singhvi, I.; Swamy, G.K. New RP-HPLC method for estimation of aripiprazole in bulk and in pharmaceutical dosage froms. Indo American J. Pharm. Res., 2014, 4, 1842-1849.
[197]
Kumari, M.V.; Eswaramma, P.; Kumar, A.E.S.; Rao, K.V.; Babu, M.N.; Begam, S.K.S. Analytical method validation of aripiprazole in pharmaceutical dosage form by RP-HPLC. World J. Pharm. Pharm. Sci., 2016, 5, 1168-1179.
[198]
Prashanthi, K.; Sravani, V.N.; Suganda, G.; Mothiram, M.; Spandana, B.; Mohan, C.H.K. Development of validated RP-HPLC method for quantitative determination of aripiprazole. Int. J. Pharm. Pharma. Res., 2016, 4, 313-321.
[199]
El-Maraghy, C.M.; Salem, H.; Amer, S.M.; Nebsen, M. Validated HPLC method for simultaneous determination of aripiprazole and coadministered clonazepam in spiked human plasma. J. Pharm. Appl. Chem., 2017, 3, 57-61.
[http://dx.doi.org/10.18576/jpac/030108]
[200]
Nagasarapu, M.R.; Dannana, G. New stability indicating high performance liquid chromatography method for the estimation of aripiprazole in bulk and their formulations. Indian J. Drugs, 2017, 5(3), 116-123.
[201]
Mandrioli, R.; Fanali, S.; Ferranti, A.; Raggi, M.A. HPLC analysis of the novel antipsychotic drug quetiapine in human plasma. J. Pharm. Biomed. Anal., 2002, 30(4), 969-977.
[http://dx.doi.org/10.1016/S0731-7085(02)00395-3] [PMID: 12408887]
[202]
Belal, F.; Elbrashy, A.; Eid, M.; Nasr, J.J. Stability indicating HPLC method for the determination of quetiapine: application to tablets and human plasma. J. Liq. Chromatogr. Relat. Technol., 2008, 31, 1283-1298.
[http://dx.doi.org/10.1080/10826070802019681]
[203]
Petruczynik, A.; Wróblewski, K.; Waksmundzka-Hajnos, M. Comparison of chromatographic conditions for analysis of selected psychotropic drugs in human serum. J. Chromatogr. Sci., 2015, 53(3), 394-400.
[http://dx.doi.org/10.1093/chromsci/bmu093] [PMID: 25190274]
[204]
Li, D.; Zou, J.; Cai, P.S.; Xiong, C.M.; Ruan, J.L. Preparation of magnetic ODS-PAN thin-films for microextraction of quetiapine and clozapine in plasma and urine samples followed by HPLC-UV detection. J. Pharm. Biomed. Anal., 2016, 125, 319-328.
[http://dx.doi.org/10.1016/j.jpba.2016.04.006] [PMID: 27085135]
[205]
Chrominfo, About science, technology, health and food, https://chrominfo.blogspot.com/2018/10/what-are-advantages-of-hptlc.html
[206]
Zaheer, Z.; Farooqui, M.; Dhaneshwar, S.R. Stability-indicating high performance thin layer chromatographic de-termination of clozapine in tablet dosage form. J. Pharm. Sci. Res., 2009, 1, 158-166.
[207]
Younes, K.M. Stability indicationg spectrophotometric and TLC desitometric methods for the determination of ari-piprazole in bulk and dosage forms. Int. J. Pharm. Pharm. Sci., 2014, 9, 542-548.
[208]
Patel, S.; Patel, N.J. Simultaneous RP-HPLC and HPTLC esti-mation of fluoxetine hydrochloride and olanzapine in tablet dosage forms. Indian J. Pharm. Sci., 2009, 71(4), 477-480.
[http://dx.doi.org/10.4103/0250-474X.57306] [PMID: 20502563]
[209]
Dhaneshwar, S.R.; Patre, N.G.; Mahadik, M.V. Stability indi-cating HPTLC method for quantitation of quetiapine fumarate in the pharmaceutical dosage form. Acta Chromatogr., 2009, 21, 83-93.
[http://dx.doi.org/10.1556/AChrom.21.2009.1.7]
[210]
Punugoti, R.A.; Jupally, V.R. Development and validation of new RP-UPLC method for the quantitative determination of olanzapine in tablet dosage form. Asian J. Pharm. Clin. Res., 2013, 6(Suppl. 3), 178-181.
[211]
Khandelwal, N.; Bharti, T.; Rajput, C.S.; Rathore, R.P.S. Ana-lytical method development and validation of olanzapine in formulated product. World J. Pharma. Res., 2015, 4, 1690-1699.
[212]
Thakkar, R.S.; Saravaia, H.T.; Ambasana, M.A.; Kaila, H.O.; Shah, A.K. A chromatographic determination of aripiprazole using HPLC and UPLC: A compartiave validation study. Indian J. Pharm. Sci., 2011, 73(4), 439-443.
[PMID: 22707830]
[213]
Chakravarti, B.; Chakravarti, D.N. Liquid chromatography-tandem mass spectrometry-application for clinical chemistry laboratory. J. Mol. Biomark. Diagn., 2015, 6, 244.
[http://dx.doi.org/10.4172/2155-9929.1000244]
[214]
Aravagiri, M.; Marder, S.R. Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients. J. Pharm. Biomed. Anal., 2001, 26(2), 301-311.
[http://dx.doi.org/10.1016/S0731-7085(01)00410-1] [PMID: 11470207]
[215]
Zhou, Z.; Li, X.; Li, K.; Xie, Z.; Cheng, Z.; Peng, W.; Wang, F.; Zhu, R.; Li, H. Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2004, 802(2), 257-262.
[http://dx.doi.org/10.1016/j.jchromb.2003.11.037] [PMID: 15018785]
[216]
Zhang, G.; Terry, A.V., Jr; Bartlett, M.G. Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 858(1-2), 276-281.
[http://dx.doi.org/10.1016/j.jchromb.2007.08.007] [PMID: 17766202]
[217]
Urdigere, A.K.R.; Besagarahally, B.L.; Basavaiah, K. Sensitive liquid chromatography– tandem mass spectrometry method for the determination of olanzapine in human urine. Arab. J. Sci. Eng., 2012, 37, 1381-1387.
[http://dx.doi.org/10.1007/s13369-012-0249-7]
[218]
Josefsson, M.; Roman, M.; Skogh, E.; Dahl, M.L. Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid. J. Pharm. Biomed. Anal., 2010, 53(3), 576-582.
[http://dx.doi.org/10.1016/j.jpba.2010.03.040] [PMID: 20452161]
[219]
Kirchherr, H.; Kühn-Velten, W.N. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2006, 843(1), 100-113.
[http://dx.doi.org/10.1016/j.jchromb.2006.05.031] [PMID: 16798119]
[220]
Wang, Y.; Wang, J.; Xia, X.; Wang, R.; Chen, S.; Wang, Z.; Qui, X. Quantitative determination of clozapine in rat plasma by liquid chromatography mass spectrometry and its application. Lat. Am. J. Pharm., 2013, 32, 668-673.
[221]
Caloro, M.; Lionetto, L.; Cuomo, I.; Simonetti, A.; Pucci, D.; De Persis, S.; Casolla, B.; Kotzalidis, G.D.; Sciarretta, A.; De Filippis, S.; Simmaco, M.; Girardi, P. An improved simple LC-MS/MS method for the measurement of serum aripiprazole and its major metabolite. J. Pharm. Biomed. Anal., 2012, 62, 135-139.
[http://dx.doi.org/10.1016/j.jpba.2012.01.003] [PMID: 22300908]
[222]
Ravinder, S.; Bapuji, A.T.; Mukkanti, K.; Raju, D.R.; Ravikiran, H.L.V.; Reddy, D.C. Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. J. Chromatogr. Sci., 2012, 50(10), 893-901.
[http://dx.doi.org/10.1093/chromsci/bms087] [PMID: 22767645]
[223]
Patel, D.S.; Sharma, N.; Patel, M.C.; Patel, B.N.; Shrivastav, P.V.; Sanyal, M. LC– MS/MS assay for olanzapine in human plasma and its application to a bioequivalence study. Acta Pharm. Sin. B, 2012, 2(5), 481-494.
[http://dx.doi.org/10.1016/j.apsb.2012.02.009]
[224]
Bonde, S.L.; Bhadane, R.P.; Gaikwad, A.; Gavali, S.R.; Katale, D.U.; Narendiran, A.S. Simultaneous determination of Olanzapine and Fluoxetine in human plasma by LC-MS/MS: its pharmacokinetic application. J. Pharm. Biomed. Anal., 2014, 90, 64-71.
[http://dx.doi.org/10.1016/j.jpba.2013.10.033] [PMID: 24334191]
[225]
Choong, E.; Rudaz, S.; Kottelat, A.; Guillarme, D.; Veuthey, J.L.; Eap, C.B. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. J. Pharm. Biomed. Anal., 2009, 50(5), 1000-1008.
[http://dx.doi.org/10.1016/j.jpba.2009.07.007] [PMID: 19683888]
[226]
Song, M.; Yu, X.; Zhao, H.; Hang, T.; Yang, L.; Xu, W. LC-MS-MS determination and pharmacokinetic study of clozap-ine in human plasma. Chromatographia, 2009, 69(9–10), 1049-1054.
[http://dx.doi.org/10.1365/s10337-009-0975-5]
[227]
Kubo, M.; Mizooku, Y.; Hirao, Y.; Osumi, T. Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2005, 822(1-2), 294-299.
[http://dx.doi.org/10.1016/j.jchromb.2005.06.023] [PMID: 16005688]
[228]
Barrett, B.; Holcapek, M.; Huclová, J.; Borek-Dohalský, V.; Fejt, P.; Nemec, B.; Jelínek, I. Validated HPLC-MS/MS method for determination of quetiapine in human plasma. J. Pharm. Biomed. Anal., 2007, 44(2), 498-505.
[http://dx.doi.org/10.1016/j.jpba.2007.03.034] [PMID: 17499470]
[229]
Skibinski, R. A study of photodegradation of quetiapine by the use of LC-MS/MS method. Cent. Eur. J. Chem., 2012, 10, 232-240.
[230]
Ming, D.S.; Heathcote, J. Therapeutic drug monitoring of clozapine and norclozapine in human serum using ultra-performance liquid chromatography- tandem mass spectrometry. J. Anal. Toxicol., 2009, 33(4), 198-203.
[http://dx.doi.org/10.1093/jat/33.4.198] [PMID: 19470221]
[231]
Niederländer, H.A.G.; Koster, E.H.M.; Hilhorst, M.J.; Metting, H.J.; Eilders, M.; Ooms, B.; de Jong, G.J. High throughput therapeutic drug monitoring of clozapine and metabolites in serum by on-line coupling of solid phase extraction with liquid chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2006, 834(1-2), 98-107.
[http://dx.doi.org/10.1016/j.jchromb.2006.02.042] [PMID: 16527550]
[232]
Demacker, P.N.M.; Beijers, A.M.; Daal, V.H. Van den O.J.M.W. Assay of eight tricyclic antidepressants and nor clozapine by UPLC-MS/MS. Ned. Tijdschr. Klin. Chem. Labgeneesk, 2009, 34(4), 224-225.
[233]
Rao, L.V.; Snyder, M.L.; Vallaro, G.M. Rapid liquid chromatography/tandem mass spectrometer (LCMS) method for clozapine and its metabolite N-desmethyl clozapine (norclozapine) in human serum. J. Clin. Lab. Anal., 2009, 23(6), 394-398.
[http://dx.doi.org/10.1002/jcla.20345] [PMID: 19927349]
[234]
Hass, S.E.; Brum, L., Jr; De Andrade, C.; Azeredo, F.J.; Pigatto, M.; Torres, B.G.S.; Guterres, S.S.; Costa, T.D. Highly sen-sitive LC-MS/MS method for determination of clozapine in rat plasma: Application to a preclinical pharmacokinetic study. J. Liq. Chromatogr. Technol., 2012, 35, 2873-2883.
[http://dx.doi.org/10.1080/10826076.2011.639118]
[235]
Zhang, G.; Terry, A.V., Jr; Bartlett, M.G. Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma. Rapid Commun. Mass Spectrom., 2007, 21(6), 920-928.
[http://dx.doi.org/10.1002/rcm.2914] [PMID: 17295424]
[236]
Wohlfarth, A.; Toepfner, N.; Hermanns-Clausen, M.; Auwärter, V. Sensitive quantification of clozapine and its main metabolites norclozapine and clozapine-N-oxide in serum and urine using LC-MS/MS after simple liquid-liquid extraction work-up. Anal. Bioanal. Chem., 2011, 400(3), 737-746.
[http://dx.doi.org/10.1007/s00216-011-4831-8] [PMID: 21394453]
[237]
Li, K.Y.; Zhou, Y.G.; Ren, H.Y.; Wang, F.; Zhang, B.K.; Li, H.D. Ultra-performance liquid chromatography-tandem mass spectrometry for the determination of atypical antipsychotics and some metabolites in in vitro samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 850(1-2), 581-585.
[http://dx.doi.org/10.1016/j.jchromb.2006.12.051] [PMID: 17257911]
[238]
Patel, D.P.; Sharma, P.; Sanyal, M.; Shrivastav, P.S. SPE-UPLC-MS/MS method for sensitive and rapid determination of aripiprazole in human plasma to support a bioequivalence study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2013, 925, 20-25.
[http://dx.doi.org/10.1016/j.jchromb.2013.02.022] [PMID: 23510852]
[239]
Al-Bukhaiti, W.Q.; Noman, A.; Qasim, A.S.; Al-Farga, A. Gas chromatography: principles, advantages and applications in food analysis. Int. J. Agric. Innov. Res., 2017, 6, 123-128.
[240]
Richter, K. Determination of clozapine in human serum by capillary gas chromatography. J. Chromatogr. A, 1988, 434(2), 465-468.
[http://dx.doi.org/10.1016/S0378-4347(88)80014-8] [PMID: 3246536]
[241]
Vardakou, I.; Dona, A.; Pistos, C.; Alevisopoulos, G.; Athanaselis, S.; Maravelias, C.; Spiliopoulou, C. Validated GC/MS method for the simultaneous determination of clozapine and norclozapine in human plasma. Application in psychiatric patients under clozapine treatment. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2010, 878(25), 2327-2332.
[http://dx.doi.org/10.1016/j.jchromb.2010.07.001] [PMID: 20674521]
[242]
da Fonseca, B.M.; Moreno, I.E.D.; Barroso, M.; Costa, S.; Queiroz, J.A.; Gallardo, E. Determination of seven selected antipsychotic drugs in human plasma using microextraction in packed sorbent and gas chromatography-tandem mass spectrometry. Anal. Bioanal. Chem., 2013, 405(12), 3953-3963.
[http://dx.doi.org/10.1007/s00216-012-6695-y] [PMID: 23314486]
[243]
Liang, F.; Terry, A.V.; Bartlett, M.G. Determination of aripiprazole in rat plasma and brain using ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Biomed. Chromatogr., 2012, 26(11), 1325-1332.
[http://dx.doi.org/10.1002/bmc.2698] [PMID: 22259043]
[244]
Jin, W.; Xu, Q.; Li, W. Determination of clozapine by capillary zone electrophoresis following end-column amperometric detection with simplified capillary/electrode alignment. Electrophoresis, 2000, 21(7), 1415-1420.
[http://dx.doi.org/10.1002/(SICI)1522-2683(20000401)21:7<1415:AID-ELPS1415>3.0.CO;2-M] [PMID: 10826689]
[245]
Pacáková, V.; Coufal, P.; Stulík, K.; Gas, B. The importance of capillary electrophoresis, capillary electrochromatography, and ion chromatography in separations of inorganic ions. Electrophoresis, 2003, 24(12-13), 1883-1891.
[http://dx.doi.org/10.1002/elps.200305454] [PMID: 12858364]
[246]
Hillaert, S.; Snoeck, L.; Van den Bossche, W. Optimization and validation of a capillary zone electrophoretic method for the simultaneous analysis of four atypical antipsychotics. J. Chromatogr. A, 2004, 1033(2), 357-362.
[http://dx.doi.org/10.1016/j.chroma.2004.01.057] [PMID: 15088758]
[247]
Zhou, D.W.; Li, F.M. Determination of free clozapine concen-tration in serum and plasma by capillary electrophoresis-frontal analysis. Acta Chimi. Sin., 2004, 62(13), 1256-1259.
[248]
Raggi, M.A.; Bugamelli, F.; Mandrioli, R.; Sabbioni, C.; Volterra, V.; Fanali, S. Rapid capillary electrophoretic method for the determination of clozapine and desmethylclozapine in human plasma. J. Chromatogr. A, 2001, 916(1-2), 289-296.
[http://dx.doi.org/10.1016/S0021-9673(01)00520-9] [PMID: 11382303]
[249]
Raggi, M.A.; Casamenti, G.; Mandrioli, R.; Izzo, G.; Kenndler, E. Quantitation of olanzapine in tablets by HPLC, CZE, derivative spectrometry and linear voltammetry. J. Pharm. Biomed. Anal., 2000, 23(6), 973-981.
[http://dx.doi.org/10.1016/S0731-7085(00)00382-4] [PMID: 11095298]
[250]
Qin, H.; Song-jiu, T.; Bao-quan, C.; Liang, Z. Analysis of five antipsychotic drugs by capillary zone electrophoresis. Yaowu Fenxi Zazhi, 2001, 21, 412-414.
[251]
Musenga, A.; Saracino, M.A.; Spinelli, D.; Rizzato, E.; Boncompagni, G.; Kenndler, E.; Raggi, M.A. Analysis of the recent antipsychotic aripiprazole in human plasma by capillary electrophoresis and high-performance liquid chromatography with diode array detection. Anal. Chim. Acta, 2008, 612(2), 204-211.
[http://dx.doi.org/10.1016/j.aca.2008.02.046] [PMID: 18358867]
[252]
Shahrokhian, S.; Kamalzadeh, Z.; Hamzehloei, A. Electrochemical determination of clozapine on MWCNTs/new coccine doped PPY modified GCE: an experimental design approach. Bioelectrochemistry, 2013, 90, 36-43.
[http://dx.doi.org/10.1016/j.bioelechem.2012.10.002] [PMID: 23178559]
[253]
Manjunatha, J.G.; Swamy, B.E.K.; Mamatha, G.P.; Gilbert, O.; Srinivas, M.T.; Sherigara, B.S. Electrochemical studies of clozapine drug using carbon nanotubes-SDS modified carbon paste electrode: a cyclic voltammetry study. Pharma Chem., 2011, 3(2), 236-249.
[254]
Mashhadizadeh, M.H.; Afshar, E. Electrochemical investiga-tion of clozapine at TiO2 nanoparticles modified carbon paste electrode and simultaneous adsorptive voltammetric determination of two antipsuchotic drugs. Electrochim. Acta, 2013, 87(1), 816-823.
[http://dx.doi.org/10.1016/j.electacta.2012.09.004]
[255]
Farhadi, K.; Karimpour, A. Electrochemical behavior and determination of clozapine on a glassy carbon electrode modified by electrochemical oxidation. Anal. Sci., 2007, 23(4), 479-483.
[http://dx.doi.org/10.2116/analsci.23.479] [PMID: 17420556]
[256]
Arvand, M.; Shiraz, M.G. Voltammetric determination of clozapine in pharmaceutical formulations and biological fluids using an in situ surfactant-modified carbon ionic liquid electrode. Electroanal., 2012, 24, 683-690.
[http://dx.doi.org/10.1002/elan.201100587]
[257]
Hammam, E.; Tawfik, A.; Ghoneim, M.M. Adsorptive stripping voltammetric quantification of the antipsychotic drug clozapine in bulk form, pharmaceutical formulation and human serum at a mercury electrode. J. Pharm. Biomed. Anal., 2004, 36(1), 149-156.
[http://dx.doi.org/10.1016/j.jpba.2004.04.012] [PMID: 15351059]
[258]
El-Shal, M.A. Electrochemical studies for the determination of quetiapine fumarate and olanzapine antipsychotic drugs. Adv. Pharm. Bull., 2013, 3(2), 339-344.
[PMID: 24312858]
[259]
Lawrywianiec, M.; Smajdor, J.; Bator, B.P.; Piech, R. Applica-tion of a glassy carbon electrode modified with carbon black nanoparticles for highly sensitive voltammetric determination of quetiapine. Anal. Methods, 2017, 9(47), 6662-6668.
[http://dx.doi.org/10.1039/C7AY02140B]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 8
Year: 2020
Published on: 27 September, 2020
Page: [989 - 1019]
Pages: 31
DOI: 10.2174/1573412915666190328214323
Price: $65

Article Metrics

PDF: 22
HTML: 1



Most Downloaded Article(s)